Biotechnology is improving nearly every industry it touches. As our reliance on biologically engineered products increases, what steps are being taken to keep the discipline sustainable and its practices environmentally sound?
Here are three ways biotechnology is becoming more ecologically sustainable.
1.The impact of agricultural biotechnology.
There’s a lot we’ve yet to learn about genetically modifying agricultural products, but all signs point to GMOs being one of the best tools available to fight everything from climate change to the obesity crisis. Long term data is just beginning to be realized, but one recent study in particular points to a 5.2% value increase and reduced greenhouse emissions of over 26.7 billion kilograms among GM-friendly agricultural regions over the last 20 years alone. Biotechnology is impacting agriculture in a big way and the effects are trickle-down. Countries that are embracing ag technology are improving their food supplies (keeping citizens healthier), reducing their drain on precious environmental resources, and decreasing the amount of land that must be dedicated to farming. As the related science of biomedical technology moves forward, so too will its reliance on the continued production of feedstock and other related raw materials.
2. Big Pharma looks to biotech.
One of the greatest opportunities in biotech lies in big pharmaceutical brands’ increased reluctance to delve into the nuts and bolts of research. Between regulatory burdens and market valuations, pharmaceuticals are more and more turning to biotech specialists as the gatekeepers to healthcare’s newest developments. An influx of research capital from large pharmaceutical companies will help further the end-goal of biotechnology researchers to develop more effective, less wasteful solutions for common healthcare concerns.
3. The rise of precision medicine.
Drug makers are always looking for new opportunities to segment and target their markets. Precision medicine is challenging the healthcare industry to think smaller-scale and thus, more sustainably. Highly-targeted medicine reduces trial-and-error drug waste. Precision medicine resolves the issue of “orphan drugs” and operates off from foundations of augmentable treatment options designed to be implemented on an individual level. As precision medicine takes off, sustainability will – and should – continue to be a key concern.
IMCS is more than just a biotechnology company, we’re a solutions provider. Our partners include biopharmaceutical brands, governmental agencies, and academic research labs, to name a few. We’re heavily invested in making sure the biotechnology industry grows in a thoughtful, sustainable way.
Would you like to find out more about our game-changing products? Contact us today.